Drug intelligence / Profile preview

SNUBH-NM-333 F-18

Development stage: Unknown
Lead developer: Seoul National University Bundang Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

SNUBH-NM-333 F-18 is a fluorine-18 labeled radiotracer developed as a novel probe for in vivo imaging of amyloid plaques, primarily used in positron emission tomography (PET) scans. It is under clinical investigation for its ability to detect amyloid pathology, which is relevant to neurodegenerative diseases such as Alzheimer's disease. The compound has the molecular formula C14H11FN2S and a molecular weight of 257.32. Its mechanism involves binding to amyloid plaques, allowing visualization and quantification through PET imaging.

Targets

Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on SNUBH-NM-333 F-18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNUBH-NM-333 F-18.